Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 15 of 15 publications.
Skip to main content
Andrews EB, Gilsenan A, Midkiff K, Harris D. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma - Editorial. Ann Epidemiol. 2016 Nov;26(11):751-3. doi: 10.1016/j.annepidem.2016.08.011
Dal Pan G, Spooner A, Morrato E, Smith M, Jones J, Wise L, Gilsenan A. Introduction to the evaluation of therapeutic risk management programs. Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2016. Dublin, Ireland. Previously presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Andrews E, Sturmer T, McGrath LJ, Johnson Funk M, Lund JL, Johannes CB, Gilsenan AW, Powers C. Exploring innovative methods to conduct validation using United States Medicare administrative claims data. Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(S3):50.
Arana A, Varas-Lorenzo C, McQuay LJ, Ziemiecki R, Bui CL, Gilsenan AW, Rothman KJ, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Margulis AV, Perez Gutthann S. Do individual antimuscarinic drugs to treat overactive bladder have different cardiovascular risks? A UK CPRD cohort study. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):534-5.
Midkiff KD, Andrews EB, Gilsenan AW, Deapen M, Harris DH, Schymura MJ, Hornicek FJ. The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication. Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):960-8. doi: 10.1002/pds.4008
McGrath LJ, Rulgomez A, Plana E, Fortuny J, Garcia-Rodriguez L, Rebordosa C, Varas-Lorenzo C, Ziemiecki R, Gilsenan AW, Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.
Plana E, McGrath LJ, Fortuny J, Ruigomez A, Fernandez-Cantero O, Garcia-Rodriguez LA, Gilsenan AW, Andrews E, Rebordosa C, Ziemiecki R. An algorithm to identify duplicate patients when pooling aggregate data from two primary care databases in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58-9. doi: 10.1002/pds
Harris D, Midkiff K, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Study update for a postmarketing case series study of adult osteosarcoma and teriparatide in the United States. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):437-8.
Kellier-Steele N, Gilsenan A, Midkiff K, Harris D, Andrews E. Complementary observational studies assessing the incidence of a rare cancer outcome by linking state cancer registry data to large pharmacy claims databases in the United States. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):152.
Fortuny J, Kaye JA, Bui CL, Gilsenan AW, Bartsch J, Plana E, McQuay LJ, Calingaert B, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S, Arana A, Margulis AV. Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.
Ritchey ME, Jalbert J, Gilsenan A, Lystig T, Peng M, Kou TD, Blumentals W. The epidemiological approach to rare disease research: challenges and opportunities. Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(S3):S479.
Kellier-Steele N, Gilsenan A, Midkiff K, Harris D, Andrews E, Acquavella J. Parallel observational studies in a post-marketing setting assessing the incidence of osteosarcoma among teriparatide users versus a comparator group of nonusers by linking state cancer registry data to data from two large pharmacy claims databases. Poster presented at the North American Association of Central Cancer Registries (NAACCR) 2016 Annual Conference; June 14, 2016. St. Louis, MO.
Krohn K, Kellier-Steele N, Gilsenan A, Harding A, Andrews E. Forteo voluntary patient registry: 6-year progress on a prospective osteosarcoma surveillance study. Poster presented at the 22nd Annual Meeting of the International Society of Clinical Densitometry (ISCD); June 2016. Dublin, Ireland.
Hollis K, Gilsenan A. Design and implementation of surveys to assess patient and health care provider understanding of risks and safe use conditions. In: Andrews EB, Moore M, editors. Mann's pharmacovigilance. 3rd ed. Hoboken: NJ. John Wiley & Sons; 2014.
Andrews EB, Davis KH, DiBenedetti DB, Forsyth B, Gilsenan AW, Hollis KA, Lewis SA, Price MA, Tennis P, Zografos LJ. Risk evaluation and mitigation strategy assessments: social science methodologies to assess goals related to knowledge. 2014. Research Triangle Park: RTI Press.